Bristol Myers Squibb in an all-cash deal at $5 per share, with the merger set to close in Q2 2025. Despite Abecma generating $242 million in U.S. sales, 2seventy still booked a $3.3 million loss from ...

Board member Mick Hitchcock, named interim CEO replacing Thomas Butler.COO and President Ramses Erdtmann continuing at Biomea in current ...

Shares of Bristol Myers Squibb Co. slid 3.05% to $59.19 Tuesday, on what proved to be an all-around favorable trading session ...

"It’s as much of the marquee high-value transactions as it is the aggregation of what we call our bread and butter, and it’s that combination that ends up being magical for us in the end,” said CEO ...

"It’s as much of the marquee high-value transactions as it is the aggregation of what we call our bread and butter, and it’s ...

Bearish flow noted in Bristol Myers ( BMY) Squibb with 13,765 puts trading, or 2x expected. Most active are Apr-25 60 puts and 4/4 weekly 60 puts, with total volume in those strikes near 8,600 ...

BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to ...

After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...